Phase 1/2, Multicenter, First-In-Human, Dose Escalation and Dose ExpansionStudy of CPO107, a CD47-blocking Bispecific Fusion Protein AdministeredIntravenously to Patients with Advanced CD20-positive Non-HodgkinsLymphoma
Study of CPO107 in Patients with Non-Hodgkin's Lymphoma (NHL)
Sponsor: Conjupro Biotherapeutics Inc
Enrolling: Male and Female Patients
IRB Number: AAAU1909
U.S. Govt. ID: NCT04853329
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The main purpose of this research study is to determine if the study drug CPO107 can be used safely in participants who have been diagnosed with non-Hodgkins lymphoma (NHL) and have failed at least two prior conventional anti-cancer drugs. Other purposes of the study are to monitor how the study drug is distributed and broken down inside the body. All patients entering this study will receive CPO107 by intravenous infusion (into the vein).
Barbara Pro, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Non-Hodgkin's Lymphoma (NHL)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator